...
首页> 外文期刊>Journal of clinical biochemistry and nutrition. >Prospective Multi-Center Trial for the Efficacy of Ecabet Sodium on the Relief of Dyspepsia in Korean Patients with Chronic Gastritis
【24h】

Prospective Multi-Center Trial for the Efficacy of Ecabet Sodium on the Relief of Dyspepsia in Korean Patients with Chronic Gastritis

机译:依卡贝特钠对韩国慢性胃炎患者消化不良缓解作用的前瞻性多中心试验

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Anti-peptic and anti-inflammatory actions of ecabet sodium might be beneficial in either improving gastritis or relieving dyspeptic symptoms. This study was designed to evaluate the clinical efficacy of ecabet sodium on dyspeptic symptoms and to elucidate the molecular mechanism attributable to symptom relief in patients with chronic gastritis. Two hundred and sixty eight chronic gastritis patients with persistent dyspepsia received ecabet sodium 1 g b.i.d . for 2 weeks, after which dyspeptic symptoms were reassessed with a questionnaires as before. The changes of interleukin-8 (IL-8), inducible nitric oxide synthase (iNOS), prostaglandin E2 (PGE2), and vascular endothelial growth factor (VEGF) levels in gastric juices were measured by ELISA. The changes of nitrotyrosine in gastric mucosa were measured by immunohistochemical staining. The most common dyspeptic symptom in Korean patients with chronic gastritis was epigastric soreness (76.8%), which was improved significantly after ecabet sodium treatment (81.7%, p 2 and increased levels of VEGF were measured in gastric juices after ecabet sodium treatment, no statistical significance was noted, which might be due to high inter-individual variations. The nitrotyrosine expressions were significantly decreased after ecabet sodium treatment than before ( p <0.01). In conclusion, ecabet sodium treatment was very useful for the relief f dyspeptic symptoms in chronic gastritis, to which both attenuated inflammatory and enhanced regenerative mechanisms were contributive.
机译:依卡贝特钠的抗消化和抗炎作用可能有益于改善胃炎或缓解消化不良症状。这项研究旨在评估依卡贝特钠对消化不良症状的临床疗效,并阐明慢性胃炎患者症状缓解的分子机制。 168例持续性消化不良的慢性胃炎患者接受依卡匹钠1 g b.i.d。持续2周,然后像以前一样通过问卷调查重新评估消化不良症状。白细胞介素8(IL-8),诱导型一氧化氮合酶(iNOS),前列腺素E 2 (PGE 2 )和血管内皮生长因子(VEGF)的变化通过ELISA测量胃液中的水平。免疫组化染色检测胃黏膜中硝基酪氨酸的变化。在韩国慢性胃炎患者中,最常见的消化不良症状是上腹酸痛(76.8%),在接受依卡贝特钠治疗后明显改善(81.7%,p 2 ),并观察到依卡贝特钠后胃液中的VEGF水平升高治疗后,没有统计学意义,这可能是由于个体间的高度差异所致; ecabet钠治疗后硝基酪氨酸表达明显降低(p <0.01)。慢性胃炎的消化不良症状,其减轻的炎症反应和增强的再生机制都是造成这种情况的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号